Form 4: Theravance Biopharma Exec Reports Share Transactions

Rick E. Winningham, CEO of Theravance Biopharma, Inc., reported transactions involving ordinary shares, including the acquisition of 75,000 shares.

Summary

• Rick E. Winningham, Chief Executive Officer and Director of Theravance Biopharma, Inc., has reported a transaction involving ordinary shares.
• On April 1, 2026, Mr. Winningham acquired 75,000 ordinary shares at a price of $0.
• Following this transaction, Mr. Winningham beneficially owns 1,651,094 ordinary shares.
• These shares are held directly and indirectly, with indirect holdings including 23,400 shares as custodian and 92,567 shares by trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider share transactions without indicating significant positive or negative developments for the company.

Positives

• Acquisition of 75,000 ordinary shares by the CEO at no cost, indicating potential confidence or compensation.
• The CEO's total beneficial ownership remains substantial at 1,651,094 shares.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company executives and directors. Such filings are crucial for investors monitoring insider sentiment and ownership structure.

Stakeholder Impact

• Shareholders: Gain insight into insider shareholdings and potential confidence signals from the CEO.
• Employees: May observe executive compensation practices related to share acquisition.
• Creditors: No direct impact from this filing.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, SEC Filing, Stock Transaction, Beneficial Ownership, Rick E. Winningham, CEO, Director, Ordinary Shares